Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of HRS-2183 in Healthy Chinese Subjects
NCT07232758Phase 1Completed
- Sponsor
- Hengrui
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing Treatment group A:HRS-2183 with Treatment group B:placebo (2 arms). Primary endpoint: Incidence and severity of any adverse events at day 16. Started Oct 2025; status: completed.
02
Drugs
HRS-2183
Beyond the preview
Go deeper on NCT07232758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232758.